The estrogen levels of Asian women are different from those of Western women, and this could affect estrogen receptor (ER) bioactivity and breast cancer risk. We conducted a case-control study in 169 postmenopausal breast cancer cases and 426 matched controls nested within a population-based prospective cohort study, the Singapore Chinese Health Study, to evaluate the serum levels of estrogens and their receptor (ERa and ERb)-mediated estrogenic activities in relation to breast cancer risk. Breast cancer cases had higher levels of estrogens and ER-mediated bioactivities in baseline serum than the controls. Compared with those in the lowest quartile, women in the highest quartile for estrone (E 1 ) or ERa-mediated bioactivity had increased breast cancer risk. After additional adjustment for ERb bioactivity, free estradiol, and E 1 levels, serum ERa-mediated bioactivity remained associated with increased breast cancer risk. Compared with those in the lowest quartile, women in the highest quartile for ERa-mediated bioactivity had an odds ratio of 2.39 (95% CIZ1.17-4.88; P for trendZ0.016). Conversely, the positive association between E 1 and cancer risk became null after adjustment for ERa-mediated bioactivity, suggesting that the effect of E 1 could be mediated through ERa. Factor(s) contributing to increased ERa-mediated estrogenic bioactivity in serum and its role as a predictor for breast cancer risk need to be validated in future studies.
Introduction
There is ample experimental, epidemiological, and clinical evidence linking estrogens and breast cancer risk (Henderson & Feigelson 2000 , Russo & Russo 2006 . Several established risk factors for breast cancer are strongly associated with sex hormone levels, suggesting that these factors affect estrogen signaling pathways to impact breast cancer risk (Key et al. 2011) . Endogenous hormone levels have been used to estimate breast cancer risk in nine previous prospective studies carried out in postmenopausal women (Key et al. 2002) . An analysis of pooled data from these studies indicated that postmenopausal women with relatively high serum levels of sex hormones such as estradiol (E 2 ) and testosterone had a roughly twofold higher risk of breast cancer compared with those with lower levels. Of these studies, all, but one in Japan (Kabuto et al. 2000) , were conducted in North America or Europe where women are known to have a higher BMI compared with their leaner Asian counterparts and also more likely to use hormone replacement therapy. Obesity could contribute to higher estrogen levels, as adipose tissues are a source of estrogens in postmenopausal women (Siiteri 1987) . Furthermore, marked differences in circulating estrogen levels have been reported between Asian and Caucasian women , Shimizu et al. 1990 , Wu & Pike 1995 .
Estrogen receptor a (ERa) and ERb bioassays are classically used to identify estrogenic compounds present in the environment or to detect persistent organic pollutants in the serum of humans (Hjelmborg et al. 2006 , Kanno et al. 2007 , Kruger et al. 2008 , Djiogue et al. 2010 , Du et al. 2010 . Recently, using the ERa assay, it has been demonstrated that ERa-mediated bioactivity in serum can predict hip fracture risk in menopausal women (Lim et al. 2012) . The strength of such ER bioassays is that the overall effects of all factors (known and unknown) on ER activation can be quantified. Therefore, these ER bioassays measure the summated activity of all agonists and antagonists that either activate or inhibit the ERs.
In terms of breast cancer, the bioactivities of both ERa and ERb have been shown to be independently associated with increased risk in European studies (Widschwendter et al. 2009 , Fourkala et al. 2012 . Specifically, in a casecontrol study conducted in Germany, women in the highest quintile of both serum ERa and ERb bioactivities had approximately seven times higher breast cancer risk compared with those in the lower quintile (Widschwendter et al. 2009 ). More recently, in a casecontrol study nested in a cohort study of women in the UK, ERa bioactivity has been shown to be independently associated with breast cancer risk using serum collected more than 2 years before diagnosis for breast cancer cases (Fourkala et al. 2012) . These studies suggest that assays for serum ERa and ERb bioactivities may be useful for the prediction and management of breast cancer at a population level as well as in a clinical setting.
Singapore Chinese women are currently experiencing one of the highest rates of increase in breast cancer incidence globally. Over the past 35 years from 1970 to 2005, the incidence of breast cancer in Singapore has tripled from 20.0 to 60.0/100 000 (National Registry of Diseases Office 2008). Factors causing the rapid increase in this historically low-risk population are largely unclear. Utilizing prospectively collected questionnaire data and serum collected from women of a population-based cohort study in Singapore, in the present study, we investigated the associations between estrogen and ER-mediated bioactivity levels and breast cancer risk among postmenopausal women in an Asian country. We provide evidence to suggest that factors other than estrone (E 1 ) and E 2 may activate ERa-mediated signaling pathways to increase breast cancer risk.
Subjects and methods

Study population
Both cases and controls were participants of the Singapore Chinese Health Study, a population-based prospective cohort study carried out in 63 257 Chinese subjects (including 35 298 women) who were aged 45-74 years during recruitment between April 1993 and December 1998 (Hankin et al. 2001) . All the participants of this cohort study were residents of government-subsidized housing schemes, in which the majority (86%) of Singaporeans resided at the time of recruitment. Study subjects were restricted to the two major Chinese dialect groups: Hokkien and Cantonese, who originated from two contiguous prefectures in southern China. The Institutional Review Board of the National University of Singapore approved this study.
During recruitment, the subjects were interviewed in-person using a structured questionnaire to collect information on tobacco use and medical history as well as a dietary component to assess current intake patterns. In addition, information on menstrual (including menopausal status) and reproductive (including menopausal hormone therapy use) histories was collected from the women. Between April 1994 and December 1999, blood and single-void urine specimens were collected from a random 3% sample of study enrollees. Details of biospecimen collection, processing, and storage procedures have been described previously (Koh et al. 2003) . Between January 2000 and April 2005, we extended our biospecimen collection to all surviving cohort members and collected biospecimens (blood/buccal cells and urine) from 32 575 participants, representing a consent rate of about 60% of surviving cohort participants at that time.
Among the 35 298 women in this cohort, 15 415 (44%) donated blood for research. Only postmenopausal women without a history of breast cancer during recruitment were included in the present study.
Case ascertainment
Incident breast cancer cases were identified through the population-based cancer registry in Singapore (National Registry of Diseases Office 2008). All cases were further verified by manual checking of pathological and medical records. As of 28 June 2010, among 25 584 women who were postmenopausal during recruitment, 573 had developed breast cancer. Among them, 169 women with breast cancer had donated blood before cancer diagnosis and were included as cases in this study. Compared with the other breast cancer patients who did not donate a blood sample, cases in this study were younger at diagnosis (66.7 vs 64.9 years). Patients who did not donate blood samples were less educated (45.3% had no formal education) than those who did (20.7% had no formal education). Those who did not donate biospecimens were also more likely to have advanced stage of breast cancer, but less likely to use hormone replacement therapy compared with those who donated. Otherwise, there was no significant difference in BMI or prevalence of positive family history for breast cancer between the two groups of breast cancer patients.
Control selection
For each of the 169 cases, up to three control subjects were randomly selected among all the female cohort participants who had donated blood samples and who were alive and free of breast cancer at the time of cancer diagnosis of their index case. The chosen controls were matched to the index case on age at study enrollment (G3 years), dialect group (Hokkien and Cantonese), and dates of study enrollment (G2 years) and of blood collection (G6 months). Among the 169 cases, there were 19 cases having only one eligible control each and 43 cases having only two controls each. The other 107 cases had three controls each.
Blood analysis
Serum samples of a given matched set (containing the samples from the case and one to three matched controls) were arranged in a random order, identified only by unique codes, and tested in the same laboratory batch for all measurements. Laboratory personnel were blinded to case or control status of the samples. Serum samples were thawed at 4 8C and individually filtered via 0.22 mm sterile cartridges. Filtered sera were collected in aliquots for measurements of E 1 , E 2 , sex hormone-binding globulin (SHBG), and ERa-and ERb-mediated bioactivity levels.
Serum E 1 and E 2 levels were measured with liquid chromatography-tandem mass spectrometry (LC-MS/MS) using d 4 -E 1 and d 5 -E 2 as internal standards, as reported previously (Nelson et al. 2004) . The respective intra-assay and inter-assay variability (coefficient of variation (%)) ranges for E 2 were 3.9-14.5% (meanZ8.7%) and 1.2-13.3% (meanZ6.3%) under the condition of 10-1000 pM E 2 respectively. The corresponding values for E 1 were 1.3-15.7% (meanZ8.2%) and 1.7-11.5% (meanZ5.4%) under the condition of 25-1000 pM E 1 .
Serum SHBG levels were quantified with a solid-phase, two-site chemiluminescent immunoassay using the Immulite Analyzer (Siemens Medical Solutions USA Inc., Malvern, PA, USA). The solid phase was a polystyrene bead with a MAB specific for SHBG. The intra-assay and inter-assay relative standard deviation (RSD) values for SHBG in the range of 2-18 nM were 6.7 and 2.0% respectively. The percent of free E 2 was calculated from serum SHBG levels based on the following regression model: percent of free E 2 ZK0.01533!serum SHBGC2.921 (Langley et al. 1985) . Free E 2 level for each subject was then computed as the product of percent of free E 2 and total E 2 levels.
The biological activity of estrogens in serum was assessed using a validated estrogen-driven recombinant cell bioassay (Wong et al. 2007 , Li et al. 2009 ). Human uterine cervical HeLa cells (ATCC, Manassas, VA, USA) were transformed to stably express either ERa (ESR1) or ERb (ESR2). When exposed to test sera, luciferase activity expressed from these transformed HeLa cells reflects estrogenic bioactivity through four tandem copies of a consensus estrogen response element coupled to a luciferase gene stably incorporated into the genome. Such luciferase activity reflects the summated bioactivity of estrogenic ligands in serum. The expression levels of ERa or ERb in these recombinant cell lines were confirmed with immunoblotting. Strong expressions of ERa or ERb protein were detected in the ERa or ERb cell lines respectively (Fig. 1A) . HeLa cells do not express ERa, and the ERb-stable cell line does not contain any detectable ERa protein. HeLa cells do express low levels of ERb, and the ERa-stable cell line reflects this, although the predominant receptor is ERa. In the presence of the natural ligands E 1 and E 2 , the ERa and ERb cell lines exhibit dose-dependent bioactivity (Fig. 1B) .
Recombinant cells were passaged, plated in a 96-well plate in 10% charcoal-treated (CT) fetal bovine serum (FBS), and allowed to adhere overnight. Culture medium was then removed and replaced with incremental amounts of E 2 in 10% male human serum (Sigma) stripped of steroids using charcoal treatment for calibration standards. Stock solutions of E 2 were prepared in serum and diluted to 10% using culture medium (Eagle's Minimum Essential Medium), and duplicates of each concentration were included in the plate. Similarly, test serum was also diluted to 10% using culture medium and added to the cells in duplicates. Baseline level of E 2 in CT human serum is about 20 pM tested using LC-MS/MS. After an incubation period of 24 h, the medium was decanted, and the cells were washed with PBS and lysed with the Mammalian Protein Extraction Reagent (MPER) obtained from Thermo Scientific (Rockford, IL, USA). Luciferase activity was measured using the Luciferase Assay System (Promega) on the Glomax 96-well Microplate Luminometer (Promega) .
All test sera were tested on the same day using the same batch of cells. Calibration standards and quality control (QC) samples were included in every 96-well plate. Readings from the plate were used if QC samples in that plate had relative errors !30%. If the relative error was O30%, the assay was repeated. The mean (S.D.) of relative errors for ERa bioassay was 5.85% (5.16) and for ERb bioassay was 11.51% (7.87).
Calibration curves were fitted with a regression model that visually best fits the points within the range of the test samples and maximizes the correlation coefficient (R 2 ) value. The R 2 values for ERa and ERb ranged from 0.96 to 0.99. Total estrogen-mediated activity was calculated based on the average luminescence readings for each test serum, and it is expressed as pM E 2 equivalent obtained by interpolation from calibration curves in each plate. Microsoft Excel Software was used for curve fitting and interpolation. For the ERa bioassay, the calibration curve ranged from 5 to 70 pM, with intra-assay and interassay RSD values of 6 and 14% respectively (Fig. 1C, upper panel) . For the ERb bioassay, the calibration curve ranged from 5 to 250 pM, and the intra-assay and inter-assay RSD values were 8.1 and 16% respectively (Fig. 1C , lower panel). Five serum samples had ERb values below the detection limit and were thus omitted from the analysis.
Statistical analysis
The distributions of all biomarkers measured were markedly skewed with a long tail toward high values, which were corrected, to a large extent, by transforming the original values to logarithmic values. Therefore, a formal statistical test was carried out on logarithmically transformed values and geometric (as opposed to arithmetic) means were obtained. The analysis of covariance (ANCOVA) method was used to examine the differences in ERα dose-response curves the levels of serum biomarkers between breast cancer cases and control subjects with adjustment for other covariates, namely BMI (!20, 20-!24, 24-!28, and 28C kg/m 2 ), number of live births (none, one to two, three to four, and five or more), age at menarche (!13, 13-14, 15-16, and 17C years) , use of hormone replacement (yes, no) and family history of breast cancer (yes, no). We also included set number as a covariate to account for the matched case-control design in this study. We used the conditional logistic regression method to examine the associations between serum biomarkers measured and breast cancer risk in our main analysis. For subanalysis involving stratification by receptor positivity of breast cancer cases and time between blood draw and diagnosis, unconditional logistic regression models that included all the controls in this study were used to examine the association between serum biomarkers and breast cancer risk. In this study, our aim was to determine how estrogen and bioactivity levels in cases compared with those in the controls might affect breast cancer risk. Hence, study subjects were grouped into quartiles of individual serum parameters based on their distributions among control subjects because they formed the baseline or comparison group. Furthermore, in the general population, as the number of women without breast cancer far exceeds that of those with breast cancer, the levels in a population are essentially defined by the levels in the controls. The magnitude of the association was assessed by odds ratio (OR) and its corresponding 95% CI and P value. An additional analysis also included quartile levels of E 1 , free E 2 , SHBG, and ERa-and ERb-mediated bioactivities in the same model. For the unconditional logistic regression analyses, age at blood draw was included as a covariate. All the analyses were carried out using the SAS, version 9.1 (SAS Institute, Inc., Cary, NC, USA). All P values reported are two sided. The statistical significance level was set at a two-sided P value of 0.05.
Results
For the 169 breast cancer cases, the mean time interval from blood draw to breast cancer diagnosis was 4.0 years (S.D. 2.5 years), and only 43 cases (25%) had blood drawn within 2 years of cancer diagnosis. The mean age at cancer diagnosis was 64.9 (S.D. 7.5; range 48.3-82.0) years. Compared with the controls, a higher proportion of women with breast cancer had BMI R24 kg/m 2 , had secondary school education or higher, were nulliparous or had fewer live births, and were older at the first live birth, which were observations similar to previous results published for this cohort of women (Koh et al. 2003) . Only 6.1% among the controls and 10.7% among the cases used hormone replacement therapy (Table 1) . Breast cancer cases tended to have increased circulating serum E 1 , E 2 , free E 2 , and ERa-and ERb-mediated bioactivity levels, but lower serum SHBG levels than the controls, although only the differences for E 1 , free E 2 , and ERa-mediated bioactivity levels reached statistical significance (Table 2) . After adjusting for BMI, number of live births, age at menarche, use of hormone replacement, and family history of breast cancer, borderline dosedependent activity was observed for E 1 , which exhibited an association with a 60% increase in risk for women in the highest quartile relative to those in quartile 1 (OR, 1.60; 95% CI, 0.94-2.72; P for trendZ0.05; Table 3 ). There were no clear dose-dependent associations between serum total E 2 , free E 2 , SHBG, and ERb-mediated activity levels and breast cancer risk. Strikingly, compared with that in women in the lowest quartile, ERa-mediated bioactivity was associated with a dose-dependent increase in breast cancer risk, ranging from a 45% higher risk in women in quartile 2 to a 159% higher risk in those in the highest quartile (OR, 2.59; 95% CI, 1.44-4.65; P for trendZ0.001; Table 3 ). Reanalysis done with a minimal value (20 pM) assigned to five values of ERb below the limit of detection yielded essentially the same results; there was no significant association between serum ERb (!20, 20-!24, 24-!28 , and 28C kg/m 2 ), number of live births (none, one to two, three to four, and five or more), age at menarche (!13, 13-14, 15-16, and 17C years) , use of hormone replacement therapy (yes, no), and family history of breast cancer (yes, no); Model 3, adjusted for covariates in Model 1 and also quartile values of serum estrone, free estradiol or total estradiol (for SHBG), SHBG, ERa activity, and ERb activity; OR, odds ratio. levels and breast cancer risk. To examine the independent effect of individual estrogenic factors measured on breast cancer risk, further adjustment for E 1 , free E 2 , SHBG, and ERa-and ERb-mediated bioactivity levels was done (Table 3 , last column). After adjusting for ERa-mediated activity, the dose-dependent relationship between E 1 and breast cancer risk was no longer evident; the ORs (95% CI) for those in quartiles 2, 3, and 4 were 0.80 (0.45-1.42), 0.88 (0.49-1.57), and 1.08 (0.58-1.99) respectively (P for trendZ0.74), suggesting that ERa-mediated bioactivity was primarily responsible for the effect of E 1 on breast cancer risk. Additional adjustment for free E 2 , SHBG, and ERb bioactivity levels did not materially change the risk estimates (Table 3) . By contrast, even after adjusting for E 1 , free E 2 , SHBG, and ERb bioactivity levels, the strong association with ERa-mediated activity was essentially unaltered with a 2.4-fold increase (OR, 2.39; 95% CI, 1.17-4.88; PZ0.016) in breast cancer risk (Table 3) . To further delineate the role of serum ERa bioactivity, we also carried out an analysis to compare risk in ERa-positive or ERanegative tumor cases. Data on ER status were available for 58.6% of the breast cancer cases. There were 69 ERapositive and 30 ERa-negative breast cancer diagnoses. The results suggested that the positive association between ERa-mediated activity and breast cancer risk was present in both subtypes of breast cancer. Compared with those of women in the lowest quartile, the ORs (95% CI) of women in the highest quartile were statistically significant at 2.43 (1.00-5.94) for ER-positive breast cancer and 3.63 (1.01-13.08) for ER-negative breast cancer (Table 4) .
Finally, we examined the association between ERamediated activity and breast cancer risk by time between blood draw to cancer diagnosis. Risk estimates obtained from the analysis of cases with blood drawn within 2 years of cancer diagnosis were essentially similar to those obtained from the analysis of cases with blood drawn more than 2 years before cancer diagnosis. Although the P for trend was of borderline statistical significance (PZ0.08) for the analysis limited to cases with blood drawn more than 2 years before cancer diagnosis, relative to those in the lowest quartile, women in the highest quartile in this group still had significantly increased breast cancer risk (OR, 2.15; 95% CI, 1.07-4.33; Table 5 ).
Discussion
This is the first study to investigate the effect of estrogens and ERa-and ERb-mediated bioactivities on the risk of breast cancer in Chinese postmenopausal women. (!20, 20-!24, 24-!28 , and 28C kg/m 2 ), number of live births (none, one to two, three to four, and five or more), age at menarche (!13, 13-14, 15-16, and 17C years), use of hormone replacement therapy (yes, no), family history of breast cancer (yes, no), and quartile value of estrone and free estradiol levels. OR, odds ratio. (!20, 20-!24, 24-!28 , and 28C kg/m 2 ), number of live births (none, one to two, three to four, and five or more), age at menarche (!13, 13-14, 15-16, and 17C years) , use of hormone replacement therapy (yes, no), family history of breast cancer (yes, no), and quartile value of estrone and free estradiol levels. OR, odds ratio.
Our data demonstrated that higher levels of ERa-mediated bioactivity in sera were associated with an increased risk of cancer and that estrogens, especially E 1 , influenced cancer risk via interaction with ERa in the pathogenesis of postmenopausal breast cancer.
The geometric means of total free E 2 , E 1 , and ERa bioactivity levels were significantly higher in pre-disease serum collected from breast cancer cases than in that from controls. However, after dividing the biomarker levels into quartiles and assessing their association with breast cancer risk, a borderline dose-dependent relationship was also observed with the highest quartile of E 1 exhibiting a 60% higher risk of breast cancer. Although high E 2 levels are known to be associated with a higher risk of breast cancer in postmenopausal women (Kabuto et al. 2000 , Key et al. 2003 , Manjer et al. 2003 , Missmer et al. 2004 , ZeleniuchJacquotte et al. 2004 , Kaaks et al. 2005 , Eliassen et al. 2006 , Baglietto et al. 2010 , Farhat et al. 2011 , the role of E 1 in breast cancer carcinogenesis is less well appreciated. There is evidence that E 1 levels, but not E 2 , can be higher depending on lifestyle factors. Japanese women born in the USA have mean E 1 levels higher than those in Caucasian counterparts, contrasting with the largely similar mean E 2 levels between these two populations (Probst-Hensch et al. 2000) . In that study, differences in E 1 levels were still evident after adjustment for age, weight, and androstenedione levels. On the other hand, Japanese women living in rural areas were found to have 43% lower E 1 levels compared with weight-and age-matched Caucasian women living in California (Wu & Pike 1995) , suggesting that the transition from a rural to an urban lifestyle may have a contributory effect on high E 1 levels. One lifestyle factor may be shift work, as women working graveyard shifts have been reported to have significantly higher E 1 levels (20 vs 11.5 pg/ml) compared with those who never worked night shifts (Nagata et al. 2008) . Although E 1 has 20-80% of the bioactivity of E 2 depending on the assay used (Fang et al. 2000) , its higher levels indicate that its contribution to overall estrogenicity and breast cancer risk is significant in the postmenopausal condition in our cohort. The challenge is to define the role of lifestyle modifications that may lower E 1 levels and breast cancer risk. The loss of statistically significant association with E 1 levels in this study was primarily due to adjustment for ERa activity, and we deduced that the effect of E 1 in the pathogenesis of postmenopausal breast cancer could be mediated via its binding to ERa.
Conversely, ERa-mediated bioactivity appeared to be an independent risk factor for breast cancer risk. Logistic regression analyses indicated that even after adjustment for the known factors of estrogenic action such as E 2 , E 1 , and BMI, women whose ERa-mediated bioactivity was in the highest quartile still had significantly higher breast cancer risk compared with those in the lowest quartile, suggesting that other factor(s), besides E 1 and E 2 , was acting via the ERa-mediated genomic signaling systems to increase breast cancer risk. This dose-dependent increase in risk with high ERa-mediated bioactivity was evident in periods before 4 years and within 2 years of blood draw, indicating the robustness of the association. To our knowledge, this is the first study to use mammalian cellbased bioassays to prospectively examine the relationship between ERa-mediated bioactivity and breast cancer risk. One recent UK study, utilizing a yeast-based reporter gene assay system, did not observe any overall relationship between cancer risk and receptor bioactivity. In this study (Fourkala et al. 2012) , an association between ERamediated bioactivity and breast cancer risk was only present in the subset of cases whose blood was collected more than 2 years before cancer diagnosis (Fourkala et al. 2012) . This contradicted the findings of a case-control study that the same group of investigators had conducted in Germany using blood collected from cases after clinical diagnosis and showing a strong association between ERa bioactivity and cancer risk (Widschwendter et al. 2009) . Differences between our study and the study carried out by the UK group could be due to the use of mammalian cells by us, which are more physiologically relevant to differentiate between agonists and antagonists compared with yeast cell-based bioassays used by other investigators (Widschwendter et al. 2009 , Fourkala et al. 2012 . In addition, the co-regulators involved in the transactivation of estrogen-sensitive reporter genes has been reported to differ between yeast and mammalian systems (Kohno et al. 1994) .
Although the two most abundant estrogens present in the serum (E 2 and E 1 ) can bind to ERa and activate it, many other compounds in the serum are also known to be capable of activating the receptor. These include estrogen metabolites from birth control pills and endocrinedisrupting compounds (EDCs) that have estrogenic activity. A wide range of synthetic endocrine-disrupting chemicals such as dioxins and polychlorinated biphenyls, bisphenol A, and pesticides (endosulfan, toxaphene, and dieldrin) are estrogenic compounds that can exert biological effects at trace concentrations and have the potential to provoke additive estrogenic mixture effects at low doses, even at no observed effect levels (DiamantiKandarakis et al. 2009 , Kandaraki et al. 2011 . Thus, ERa-mediated bioactivity could be a more comprehensive measurement of the combined effects of all known and unknown estrogenic compounds present in the sera of women, all of which could affect breast cancer risk. Our data indicating that the risk due to increased ERamediated bioactivity was independent of endogenous estrogens support the hypothesis that environmental factors may have a contributory role in breast cancer risk in our cohort. More research is warranted to identify these EDCs. This is consistent with the rapid increase in breast cancer rates in rapidly modernizing Singapore.
While the UK study included only ER-positive cases (Fourkala et al. 2012) , our study included both ER-positive and ER-negative breast cancer cases and showed that ERamediated bioactivity was associated with increased risk for both subtypes of cancers, suggesting that ER-negative cancer also depends on estrogenic activity for growth. Intriguingly, risk was highest in patients with ERanegative tumors, increasing 15-fold within the highest quartile of ERa bioactivity, suggesting that compounds that were activating the ERa genomic signaling cascade were also capable of activating other estrogenic signaling pathways in breast cancer tissues with absent or significantly lower levels of ERa. Reports from earlier studies showed that ovariectomy prevented the formation of both ERa-positive and ERa-negative breast cancers, thus suggesting that the estrogen-driven pathway could also play a role in the development of ER-negative breast cancer (Early Breast Cancer Trialists' Collaborative Group 1992). Hence, we hypothesize that our mammalian reporter gene assay has reflected the presence of estrogenic compounds present in the serum of ERa-negative breast cancer patients that may activate estrogen signaling in the absence of intact ERa. One example is membranebound ERa 36, a truncated estrogen-sensitive receptor present in ER-negative breast cancer, which can mediate nongenomic estrogen signaling in the carcinogenesis of ER-negative tumors (Rao et al. 2011) .
Although our data were suggestive of a 1.5-fold increase in the risk of breast cancer for women in the highest quartile, the association of breast cancer risk with ERb bioactivity did not reach statistical significance and was weaker than that with ERa bioactivity. The role of ERb in breast cancer has been controversial. Breast cancer patients who are treated with tamoxifen and have high expression levels of ERb were found to have better response and longer survival time (Esslimani-Sahla et al. 2004 , Hopp et al. 2004 . On the other hand, in ERanegative breast cancer, high ERb expression is positively correlated with poor prognostic phenotypes (Skliris et al. 2006) . Some of these ligands with preferential binding to ERb have been shown to be associated with decreased breast cancer risk. For example, genistein is a soy phytoestrogen possessing high affinity for ERb , and higher soy intake has been shown to be associated with a reduced risk of breast cancer (Iwasaki et al. 2008 , Wu et al. 2008 .
The strength of this study is the nesting of the study within a population-based prospective cohort study that allows the use of questionnaire data and blood specimens collected before the occurrence of breast cancer to reduce recall and reverse causality bias. Cancer cases were identified using a comprehensive nationwide cancer registry. The limitations of this study are that the results are based on blood samples collected at a single time point, as the natural fluctuation of biomarkers that most probably occurred equally in both cases and controls could lead to the underestimation of the true associations with breast cancer risk. In this cohort, among postmenopausal women who gave blood for research, we limited the selection of cases to women who donated blood before the occurrence of breast cancer. Differences in factors such as age and hormone replacement therapy use between breast cancer cases included and those excluded in this study were accounted for either by matching or by statistical adjustment in our analyses. Furthermore, willingness to donate blood for research did not influence the biomarker-breast cancer association in this study. In addition, we acknowledge that the presence of existing occult tumors could play a role in the association between ERa-mediated bioactivity and breast cancer risk in this group of patients with an average follow-up period of 4 years. Finally, the relatively small sample size, especially in the stratification by ER positivity, does not give us sufficient power to detect significant differences in the levels of most of the blood parameters between cases and controls.
In conclusion, ERa-mediated bioactivity in sera was independently associated with a significantly increased risk of postmenopausal breast cancer. The measurement of this serum biomarker in postmenopausal women may have the potential to be developed into a clinical index for the prediction of breast cancer risk or the monitoring of patients on chemopreventive therapy for breast cancer. Author contribution statement W-P Koh and E L Yong conceived the study. V W Lim, J Li, Y Gong, and E L Yong carried out the biomarker assays. A Jin, J-M Yuan, and W-P Koh carried out the statistical analysis. V W Lim, J-M Yuan, W-P Koh, and E L Yong drafted the manuscript. All authors edited and approved the final manuscript.
